ABVC BioPharma (ABVC) Stock Price, News & Analysis

Company Overview

ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.

Key Stats

• Today's Range: $1.89 to $2.06
• 50-Day Range: $0.83 to $2.00
• 52-Week Range: $0.40 to $2.25
• Volume: 223,385 shs
• Average Volume: 308,300 shs
• Market Capitalization: $32.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ABVC Stock Analysis - Frequently Asked Questions

How have ABVC shares performed this year?

ABVC BioPharma's stock was trading at $0.59 at the beginning of 2025. Since then, ABVC stock has increased by 228.8% and is now trading at $1.94.
View the best growth stocks for 2025 here.

How were ABVC BioPharma's earnings last quarter?

ABVC BioPharma, Inc. (NASDAQ:ABVC) posted its quarterly earnings results on Wednesday, April, 30th. The company reported ($0.06) earnings per share (EPS) for the quarter. ABVC BioPharma had a negative trailing twelve-month return on equity of 29.62% and a negative net margin of 963.46%.

When did ABVC BioPharma's stock split?

Shares of ABVC BioPharma reverse split on the morning of Tuesday, July 25th 2023. The 1-10 reverse split was announced on Tuesday, July 25th 2023. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, July 25th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did ABVC BioPharma IPO?

ABVC BioPharma (ABVC) raised $7 million in an initial public offering on Tuesday, August 3rd 2021. The company issued 1,100,000 shares at $6.25 per share.

Who are ABVC BioPharma's major shareholders?

Top institutional shareholders of ABVC BioPharma include XTX Topco Ltd (0.36%).

How do I buy shares of ABVC BioPharma?

Shares of ABVC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of ABVC BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that ABVC BioPharma investors own include Meta Platforms (META), NIO (NIO), ObsEva (OBSV), Tesla (TSLA), Alibaba Group (BABA), ChargePoint (CHPT) and Walt Disney (DIS).

Company Calendar

• Last Earnings: 4/30/2025
• Today: 6/20/2025
• Next Earnings (Estimated): 8/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ABVC
• CIK: 1173313
• Web: www.abvcpharma.com
• Phone: (510)-668-0881
• Fax: N/A
• Employees: 30
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($0.13)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.90 million
• Net Margins: -963.46%
• Pretax Margin: -666.53%
• Return on Equity: -29.62%
• Return on Assets: -14.08%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.22

Sales & Book Value

• Annual Sales: $510 thousand
• Price / Sales: 64.59
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.06 per share
• Price / Book: 32.33

Miscellaneous

• Outstanding Shares: 16,980,000
• Free Float: 14,078,000
• Market Cap: $32.94 million
• Optionable: Not Optionable
• Beta: 0.19